Related Experiment Videos
Psychiatric phenomena in Alzheimer's disease. II: Disorders of perception
Abstract:
In a sample of 178 patients with AD, visual hallucinations had been experienced by 13% and auditory hallucinations by 10%. Thirty per cent had misidentification syndromes; these were associated with a younger age and younger age at onset of illness, and proportionally more men than women were affected. There was a reduced 30-month mortality rate in this group. Subjects with hallucinations had a greater deterioration in cognitive function at 12-month follow-up, which could not be accounted for by neuroleptic medication.
Insights
In Alzheimer's disease (AD) patients, hallucinations and misidentification syndromes were observed. Misidentification syndromes were linked to younger onset and male sex, with a lower mortality rate but greater cognitive decline.
Area of Science:
- Neurology
- Psychiatry
- Gerontology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Hallucinations and misidentification syndromes are potential neuropsychiatric symptoms in AD.
- Understanding these symptoms is crucial for patient management and prognosis.
Purpose of the Study:
- To investigate the prevalence of visual and auditory hallucinations and misidentification syndromes in a cohort of Alzheimer's disease patients.
- To explore associations between misidentification syndromes and demographic/clinical factors, including age, age at onset, and sex.
- To examine the impact of hallucinations and misidentification syndromes on mortality and cognitive function.
Main Methods:
- A cohort of 178 patients diagnosed with Alzheimer's disease was studied.
- Data collected included the presence of visual hallucinations, auditory hallucinations, and misidentification syndromes.
- Patient demographics, age at onset, mortality rates over 30 months, and cognitive function at 12-month follow-up were assessed.
Main Results:
- 13% of patients experienced visual hallucinations and 10% experienced auditory hallucinations.
- Thirty percent of patients presented with misidentification syndromes.
- Misidentification syndromes were associated with younger age, younger age at onset, and a higher proportion of men.
- Patients with misidentification syndromes showed a reduced 30-month mortality rate.
- Subjects experiencing hallucinations exhibited greater cognitive deterioration at 12 months, independent of neuroleptic medication.
Conclusions:
- Hallucinations and misidentification syndromes are prevalent in Alzheimer's disease.
- Misidentification syndromes in AD are associated with specific demographic and clinical profiles and a potentially better survival outlook.
- Hallucinations, irrespective of medication, are linked to accelerated cognitive decline in AD patients.